India, June 19 -- The U.S. Food and Drug Administration has announced an immediate review of new clinical trials that involve sending American citizens' living cells to China and other hostile countries for genetic engineering and subsequent infusion back into U.S. patients - sometimes without their knowledge or consent.
FDA said the decision follows mounting evidence that some of these trials failed to inform participants about the international transfer and manipulation of their biological material and may have exposed Americans' sensitive genetic data to misuse by foreign governments, including adversaries.
FDA alleged in a press release that the Biden Administration specifically requested and approved a sweeping exemption that allowed...